Abstract: Provided are methods of treating bladder cancer (e.g., urothelial carcinoma, UC) in a subject having bladder cancer, e.g., UC, with an effective dose regimen of an anti-PD-L1 antibody, e.g., durvalumab, or an antigen binding fragment thereof. Also provided are methods in which an anti-PD-L1 antibody is used in combination with another immunotherapeutic agent, e.g., tremelimumab to treat a bladder cancer, e.g., UC, in a subject having bladder cancer. In some cases, the subject undergoing treatment is identified as having a bladder cancer or tumor that is PD-L1-low/neg, or PD-L1-high. Methods are also provided in which anti-PD-L1 antibody treatment of bladder cancer is used following a standard of care or first-line therapy in subjects who have progressed following such therapies or who have relapsed after a prior treatment regimen.

Abstract: Multi-specific binding proteins that bind a tumor associated antigen, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.

Abstract: The present invention provides novel compounds compositions and methods for (i) treating or preventing inflammation; and (ii) preventing or reducing hyperactivation of innate immune response, by inhibiting NRP1-dependent cell-signaling. Also provided are compounds, composition, and methods of specifically inhibiting SEMA3A-mediated cell signaling.

Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.

Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

Abstract: The present invention relates to a polypeptide comprising an antigen binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, methods for producing and screening for the polypeptide, a pharmaceutical composition comprising the polypeptide, methods for producing and screening for a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH, and a fusion polypeptide library including a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH.

Abstract: Provided is an antibody specific to EPHA2. A monoclonal antibody specifically binding to EPHA2, comprising a heavy chain variable region consisting of the amino acid sequence as set forth in SEQ ID NO: 20 and a light chain variable region consisting of the amino acid sequence as set forth in SEQ ID NO: 22, or a functional fragment of the monoclonal antibody specifically binding to EPHA2, and a monoclonal antibody specifically binding to EPHA2, comprising a heavy chain variable region consisting of the amino acid sequence as set forth in SEQ ID NO: 15 and a light chain variable region consisting of the amino acid sequence as set forth in SEQ ID NO: 18, or a functional fragment of the monoclonal antibody specifically binding to EPHA2.

Abstract: Provided is an antibody that specifically recognizes IL-13RA2, which can be used in the manufacture of a targeting anti-tumor medicament as well as a medicament for diagnosing a tumor.

Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.

Abstract: The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.

Abstract: Provided in the present invention are a specific antibody of BCMA and a BCMA-targeting immune effector cell, and also provided are a chimeric antigen receptor-modified T cell prepared using the antibody and the use thereof.

Abstract: The present disclosure relates to methods for using BCMA-specific binding molecules (such as a BCMA-specific chimeric antigen receptor or antibody) in combination with ?-secretase inhibitors, which can be done concurrently or sequentially, to treat or prevent a B-cell related proliferative disease, such as a cancer or autoimmune disease, or the like. A BCMA-specific binding molecule in combination with ?-secretase inhibitor can be used in, for example, adoptive immunotherapy.

Abstract: The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.

Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator inhibitor type-1 (PAI-1). The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAT-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAT-1 in the active conformational state.

Abstract: The invention relates to the field of therapy, in particular dermatology. Inventors herein identify for the first time inhibitors of matrix metalloproteinase-9 (MMP9) as active molecules for use for preventing, treating or alleviating skin depigmenting disorders in a subject in need thereof, and describe compositions and kits comprising such inhibitors as well as uses thereof. Inventors further describe a method for screening pharmaceutically active molecules suitable for preventing, treating or alleviating a depigmenting disorder as well as methods for evaluating the efficacy of a depigmenting disorder treatment involving an inhibitor of MMP9 or for monitoring the course of depigmenting disorder in a subject exposed to such a treatment.

Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.

Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.

Abstract: According to an example aspect of the present invention, there is provided a use of molar mass controlled cellulose in injection molding, extrusion and three dimensional printing applications.

Abstract: Compositions are disclosed herein comprising one or more crosslinked dextrans or crosslinked dextran-poly alpha-1,3-glucan graft copolymers. Further disclosed are processes for preparing such crosslinked materials, as well as their use in absorption applications.

Abstract: A water-soluble and/or water-swellable hybrid polymer comprising: (i) from 5 wt.-% to 95 wt.-% water-soluble and/or water-swellable polysaccharide polymer selected from the group consisting of xanthan gum, carrageenan, guar gum, chitosan, alginate and combinations thereof; (ii) from 5 wt.-% to 95 wt.-% synthetic polymer comprising up to 100 mol-% repeating units according to Formula (1a): wherein components (i) and (ii) are polymerized by radical precipitation polymerization in a polar solvent.

Abstract: A method for producing a modified polymer latex includes: adding a carboxyl group-containing compound, an anionic surfactant having a weight-average molecular weight of less than 500, and an anionic surfactant having a weight-average molecular weight of 500 or more to a polyisoprene latex; and reacting the polyisoprene with the carboxyl group-containing compound in a presence of the anionic surfactant having a weight-average molecular weight of less than 500 and the anionic surfactant having a weight-average molecular weight of 500 or more.

Abstract: A process comprising polymerizing olefin monomers and optionally comonomers in a first reactor vessel, thereby forming a raw product stream comprising polymerized solids, unreacted monomer and optionally comonomer, the polymerized solids comprising olefin polymer, volatile organic compounds (VOC) and catalyst system. Then the polymerized solids are contacted with a catalyst poison selected from carbon monoxide, carbon dioxide, oxygen, water, alcohols, amines, or mixtures thereof, thereby forming a passivated stream. The passivated stream is maintained in an agitated state within a second reactor. The passivated stream within the second reactor is then contacted with a circulating gas comprising unreacted monomer for a residence time, thereby reducing the concentration of VOC in the polymerized solids by at least 10 wt % compared to the level before entering the second reactor, thereby forming a purified olefin polymer solids stream.

Abstract: The present invention relates to a reactor system for a multimodal polyethylene polymerization process, comprising; (a) a first reactor; (b) a hydrogen removal unit arranged between the first reactor and a second reactor comprising at least one vessel connected with a depressurization equipment, preferably selected from vacuum pump, compressor, blower, ejector or a combination thereof, the depressurization equipment allowing to adjust an operating pressure to a pressure in a range of 100-200 kPa (abs); (c) the second reactor; and (d) a third reactor and the use thereof as a container.

Abstract: The present disclosure provides cellulose reactive glyoxalated vinylamide polymers which impart improved wet strength decay properties, as well as high efficiency of wet strength build in paper products. A method of preparing a cellulose reactive glyoxalated vinylamide polymer composition, and methods of its use in maunfacturing paper products, as well as the resulting paper products, are also provided.

Abstract: The present invention provides an ethylene polymer having a viscosity average molecular weight of 100×104 or more and 1,000×104 or less, in which a ratio between an isothermal crystallization time at 125° C. and an isothermal crystallization time at 123° C. obtained under specific isothermal crystallization time measurement conditions is 3.5 or more and 10.0 or less, and a degree of crystallization obtained using a differential scanning calorimeter (DSC) is 40% or more and 75% or less.

Abstract: The present invention relates to a reactor system for a multimodal polyethylene composition comprising: (a) first reactor (b) hydrogen removal unit arranged between the first reactor and a second reactor comprising at least one vessel connected with a depressurization equipment, preferably selected from vacuum pump, compressor, blower, ejector or a combination thereof, the depressurization equipment allowing to adjust an operating pressure to a pressure in a range of 100-200 kPa (abs); (c) the second reactor; and (d) a third reactor and use thereof as a pipe.

Abstract: A catalytic system based at least on a preformation monomer selected from the group consisting of 1,3-dienes, ethylene, ?-monoolefins and their mixtures, on a metallocene of formula {P(Cp)(Flu)LnG} and on an organometallic compound as cocatalyst is provided. In the formula, Ln denotes a metal atom which is a rare earth metal, G denotes a group comprising the borohydride BH4 unit or denotes a halogen atom X selected from the group consisting of chlorine, fluorine, bromine and iodine, Cp denotes a cyclopentadienyl group of formula C5H4, Flu denotes a fluorenyl group of formula C13H8, P being a group bridging the two Cp and Flu groups and comprising a silicon or carbon atom. Such a catalytic system exhibits an improved stability of the catalytic activity over time, in particular on storage.

Abstract: The present invention relates to a liquid composition comprising at least one dialkyl peroxide, in liquid form at ambient temperature, at a content comprised within a range of from 75 to 77% by weight relative to the total weight of the composition, and at least one mineral oil with viscosity greater than 15 mPa·s, measured at a temperature of 10° C. and at a shear rate of 1000 s?1. Furthermore, the invention relates to the use of said composition to modify the melt rheology of the polypropylene.

Abstract: The present disclosure generally relates to processes to produce alpha-olefin oligomers and poly alpha-olefins. In an embodiment, a process to produce a poly alpha-olefin (PAO) includes introducing a first alpha-olefin and a first catalyst system comprising a metallocene compound into a continuous stirred tank reactor or a continuous tubular reactor under first reactor conditions to form a first reactor effluent. The alpha-olefin is introduced to the reactor at a flow rate of about 100 g/hr or more. The first reactor effluent includes PAO dimer comprising at least 96 mol % of vinylidene and 4 mol % or less of trisubstituted vinylene and disubstituted vinylene, based on total moles of vinylidene, trisubstituted vinylene, and disubstituted vinylene. The method includes introducing the first reactor effluent, a second alpha-olefin and a second catalyst composition comprising an acid catalyst into a second reactor under second reactor conditions to form a second reactor effluent comprising PAO trimer.

Abstract: The present disclosure generally relates to processes to produce alpha-olefin oligomers and poly alpha-olefins. In an embodiment, the present disclosure provides a process to produce a poly alpha-olefin (PAO), the process including: introducing a C6-C32 alpha-olefin and a catalyst system comprising activator and a metallocene compound into a continuous stirred tank reactor or a continuous tubular reactor under reaction conditions, wherein the alpha-olefin is introduced to the reactor at a flow rate of about 100 g/hr or more; and obtaining a product comprising PAO dimer and optional higher oligomers of alpha-olefin, or a combination thereof, the PAO dimer comprising 96 mol % or more of vinylidene, based on total moles of vinylidene, disubstituted vinylene, and trisubstituted vinylene in the product. In at least one embodiment, a process includes functionalizing and/or hydrogenating a PAO product of the present disclosure. In at least one embodiment, a blend includes a PAO product of the present disclosure.

Abstract: The invention relates to high purity polypropylenes and polypropylene compositions suitable for injection molding in which the polypropylene is characterized by a percentage of 2,1-insertions, relative to the total number of propylene molecules in the polymer chain, of at least 0.2%; a melting temperature Tm ranging from 140° C. to 160° C. as determined according to ISO 3146; a ratio of frequencies at fixed modulus of 1000 Pa for storage shear modulus (G?) and loss shear modulus (G?) greater than 4.7; a molecular weight distribution (MWD) of at least 2.5; a number average molecular weight (Mn) of at most 45 kg/mol and Carreau-Yasuda parameters ?0, b and ? complying with the relationship: 2.18?1.715(b)?0.015(Ln ?0)2+0.944(b)2+0.0149(Ln ?0)(Ln ?)+0.0095(Ln ?)2>1 when fitted to the CY equation, said CY parameters ?0, b and ? are determined from a dynamic rheology analysis (RDA).

Abstract: Methods of making polyisobutylene and catalyst systems are described. Polyisobutylene compositions and catalyst system compositions are also described. In some embodiments, a method of making a catalyst system includes: providing a support material; calcining the support material; and forming a catalyst system by adding to the support material (a) a mixture comprising BF3, (b) a mixture comprising BF3 and a complexing agent, or (c) both. In some embodiments, a method of making a polymer composition includes providing a catalyst system comprising: (a) a support material selected from the group consisting of Al2O3, ZrO2, TiO2, SnO2, CeO2, SiO2, SiO2/Al2O3, and combinations thereof; and (b) BF3; providing a feedstock comprising isobutylene; forming a reaction mixture comprising the feedstock and the catalyst system; contacting the isobutylene with the catalyst system; and obtaining a polymer composition.

Abstract: In at least one embodiment, a process to produce a poly alpha-olefin (PAO) includes introducing a first alpha-olefin to a first catalyst system comprising activator and a metallocene compound into a continuous stirred tank reactor or a continuous tubular reactor under first reactor conditions to form a first reactor effluent. The first alpha-olefin is introduced to the reactor at a flow rate of about 100 g/hr or more. The first reactor effluent includes at least 60 wt % of PAO dimer and 40 wt % or less of higher oligomers, where the higher oligomers are oligomers that have a degree of polymerization of 3 or more. The process includes introducing the first reactor effluent and a second alpha-olefin to a second catalyst composition including an acid catalyst in a second reactor to form a second reactor effluent comprising PAO trimer.

Abstract: An underlayer film-forming composition which exhibits excellent solvent resistance, and which is capable of orthogonally inducing, with respect to a substrate, a microphase separation structure in a layer formed on the substrate, said layer including a block copolymer. The underlayer film-forming composition includes a copolymer which includes: (A) unit structures derived from styrene compounds including tert-butyl groups; (B) unit structures, other than those in (A) above, which are derived from aromatic-containing vinyl compounds which do not include hydroxy groups; (C) unit structures derived from compounds which include (meth)acryloyl groups, and do not include hydroxy groups; and (D) unit structures derived from compounds including crosslink-forming groups. The copolymerization ratios with respect to the whole copolymer are: (A) 25-90 mol %; (B) 0-65 mol %; (C) 0-65 mol %; and (D) 10-20 mol %. Unit structures including aromatics account for 81-90 mol % of (A)+(B)+(C).

Abstract: Described herein is a partially fluorinated copolymer of the formula: (I); wherein R1 is selected from F or a fluorinated methyl; R2 is selected from H, F, a methyl, or a (per)fluorinated methyl; R3? is a linear or branched fluorinated alkyl group comprising 1 to 12 carbon atoms, optionally with at least one catenated oxygen atom; p is 0, 1, or 2; r is 0 or 1; and Q comprises at least one of an hydroxide, a nitrile, an ester, a silane, a siloxane, a phosphoric acid or salt thereof, a sulphuric acid or salt thereof, an alkyl, an aryl, and combinations thereof; n is an integer of at least 2; and m is an integer of at least 2.

Abstract: A copolymer which comprises, in copolymerized form, (A) 60 to 99% by weight of at least one monoethylenically unsaturated poly-alkylene oxide monomer of the formula I in which the variables have the following meanings: X is —CH2— or —CO—, if Y is —O—; is —CO—, if Y is —NH—; Y is —O— or —NH—; R1 is hydrogen or methyl; R2 are identical or different C2-C6-alkylene radicals, which may be arranged blockwise or randomly; R3 is hydrogen or C1-C4-alkyl; n is an integer from 25 to 75, (B) 1 to 40% by weight of at least one quaternized nitrogen-containing monoethylenically unsaturated monomer selected from the group consisting of monomers of formula IIa to IId in which the variables have the following meanings: R is C1-C4-alkyl or benzyl; R? is hydrogen or methyl; Y is —O— or —NH—; A is C1-C6-alkylene; X— is halide, C1-C4-alkyl sulfate, C1-C4-alkylsulfonate and C1-C4-alkyl carbonate, (C) 0 to 10% by weight of anionic monoethylenically unsaturated monomers, and (D) 0 to 30% by weight of oth

Abstract: Disclosed is a polymer for capturing or separating leukocytes. The polymer is prepared by a polymerization reaction of monomers containing an amino and a hydroxyl. The monomer containing an amino and a hydroxyl has the structure of formula (1): In formula (1), R1 is independently selected from the group consisting of a hydrogen, a methyl, an ethyl, a hydroxyl, any one of C1 to C12 long carbon chains, and a benzene ring, R2 is independently selected from the group consisting of a hydrogen, a methyl, an ethyl, any one of from C1 to C6 long carbon chains, an amino and a benzene ring, and n is an integer of 1 to 5.

Abstract: The present invention discloses a sulfonate lycine type hydrophobic associated polymer and a preparation method thereof. A preparation process of the sulfonate lycine type hydrophobic associated polymer comprises the following steps: firstly, mixing acrylamide and acrylic acid in an aqueous solution; adjusting pH of the system to be around 6 to 8; adding 3-(dimethylamino propyl methacrylamide) propanesulfonate, N-aryl-N-alkyl (methyl) acrylamide and lauryl sodium sulfate and stirring till the solution is clear; and after nitrogen is introduced for deoxidization, adding a photoinitiator azobis (isobutylamidine hydrochloride) for performing polymerization under photoinitiation conditions.

Abstract: The present invention provides a copolymer containing a structural unit derived from 1,3,7-octatriene and a structural unit derived from butadiene and a hydride thereof. Furthermore, the present invention provides a method of producing a copolymer containing a structural unit derived from 1,3,7-octatriene and a structural unit derived from butadiene.

Abstract: A vulcanizable composition comprising rubber component, a filler, and a curing agent, where the rubber component includes a block copolymer of polybutadiene and polyisoprene, and where the block copolymer has a cis content of at least 90%.

Abstract: The present invention provides an optical member forming composition comprising a compound represented by the following formula (0):

Abstract: The present patent application relates to a thermoplastic polymer produced at least from diisocyanate and diepoxide using a catalyst, wherein the catalyst is an ionic liquid, to an associated production method and use.

Abstract: The present invention relates to a polyurethane, which is particularly suitable as binder for a printing ink, which is obtainable by reacting: a) a polyol component including: i) at least one polytetramethylene glycol, ii) at least one diol having a molecular weight of not more than 200 g/mol being different from polytetramethylene glycol, iii) at least one trivalent or higher-valent alcohol having a molecular weight of not more than 6000 g/mol, b) an isocyanate component including at least one organic diisocyanate compound and c) at least one di-functional amine compound and at least one mono-functional amine compound.

Abstract: The invention relates to a binder based on phenolic resins of the benzyl ether type and isocyanate compounds having at least two isocyanate groups, containing free phenol and free hydroxybenzyl alcohols in the polyol component. The invention further relates to mold material mixtures containing the binder and to cores, molds, or risers produced with the mold material mixtures and to the use thereof in metal casting.

Abstract: The present invention relates to a supramolecular biodegradable polymer comprising a quadruple hydrogen bonding unit (abbreviated herein as “4H-unit”), a biodegradable backbone and hard blocks and a process for preparing such a supramolecular biodegradable polymer. The supramolecular polymer is specifically suitable for biodegradable articles such as biomedical implants that need high strength and/or elasticity, e.g. medical implants in the cardio-vascular field.

Abstract: The present invention relates to a process for producing polyurethanes, preferably polyurethane foams, by reaction of compounds containing isocyanate-reactive hydrogen atoms with di- and/or polyisocyanates in the presence of one or more compounds selected from the group consisting of: NC—CHR1—CONR12—X??(I), NC—CHR2—CONR3-aryl??(II), NC—CHR4—CO2H??(III), [NC—CHR5—CO2]mYm+??(IV), wherein X represents NR6R7, OR8, CONR9R10 or COOR11, R1 to R12 each independently of one another represent H, an optionally substituted C1-C8 alkyl group or an optionally substituted aryl group, Y represents a monovalent or divalent cation and m represents 1 or 2. The present invention further relates to the polyurethanes obtainable from this process, and to the use of such polyurethanes, for example in the interior of automobiles.

Abstract: The present invention relates to a phenolic resin for use in the phenolic resin component of a two-component binder system for the polyurethane cold box process, to a two-component binder system for use in the polyurethane cold box process, to a molding material mixture for curing by contacting with a tertiary amine, to the use of a corresponding phenolic resin, of a corresponding phenol component, of a corresponding two-component binder system or of a corresponding molding material mixture. The present invention relates, moreover, to an article from the group consisting of feeders, foundry molds and foundry cores, producible from a corresponding molding material mixture, to a process for preparing a phenolic resin, and to a process for producing an article from the group consisting of feeders, foundry molds and foundry cores.

Abstract: The purpose of the present invention is to provide: an epoxy resin composition which enables the achievement of an epoxy resin cured product that exhibits excellent heat resistance, and which has both good pot life at production process temperatures and excellent curability that enables curing in a short time; and a prepreg and a fiber-reinforced composite material, each of which uses this epoxy resin composition. In order to achieve the above-described purpose, the present invention has the following configurations. Namely, an epoxy resin composition which contains at least the constituent elements [A]-[C] described below, and wherein the functional group equivalent ratio of the amino groups of the constituent element [B] to the epoxy groups of the constituent element [A] is from 0.7 to 1.

Abstract: Provided is a mixture which can be subjected to a Diels-Alder reaction, comprising polymer (I) and polymer (II), wherein the structures of the polymer (I) and the polymer (II) are as shown in (I), wherein x1, y1, x2, y2, z1 and z2 are percentage molar contents; said x1 is >0, x2 is >0, y1 is >0, y2 is >0, z1 is ?0, and z2 is ?0; x1+y1+z1, and x2+y2+z2=1; Ar1, Ar2, Ar2-1, Ar3, Ar4 and Ar4-1 are each independently selected from: an aryl, or heteroaryl group containing 5-40 ring atoms; R1 and R2 are each independently a linking group; D is a conjugated diene functional group, and A is a dienophilic functional group; and n1 is greater than 0, and n2 is greater than 0. The mixture for a Diels-Alder reaction has a very good optical performance.